<DOC>
	<DOCNO>NCT00002733</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use different way stimulate immune system stop cancer cell grow . Combining different type biological therapy , include interferon alfa , interleukin-2 , tumor infiltrating lymphocyte , may kill cancer cell . PURPOSE : Phase II trial study effectiveness biological therapy , include interferon alfa , interleukin-2 , tumor infiltrating lymphocyte , treat patient metastatic cancer .</brief_summary>
	<brief_title>Biological Therapy Treating Patients With Metastatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate failure-free survival patient metastatic cancer ( preferably melanoma renal cell ) treat autologous tumor infiltrate lymphocyte ( TIL ) , interferon alfa ( IFN-A ) , interleukin-2 ( IL-2 ) . II . Describe toxic effect cost associate therapy ass risk benefit cost benefit . III . Assess relative value administer low- high-dose TIL , well value administer IFN-A TIL , IL-2 TIL , cimetidine TIL . OUTLINE : This multicenter study . Patients stratify accord center , tumor infiltrate lymphocyte ( TIL ) dose ( low vs high ) , medical condition suitable interferon alfa ( IFN-A ) /interleukin-2 ( IL-2 ) ( yes v ) . Patients assign one two treatment regimen base entry criterion . Regimen A ( prefer ) : Patients meeting preferred entry criterion receive IFN-A subcutaneously day 1-4 , TIL expand vitro IL-2 IV day 5 , IL-2 IV continuously 72 hour follow TIL infusion . Regimen B : All patient receive TIL infusion follow oral cimetidine every 6 hour 4 week . Treatment repeat regimens every 3-6 week absence disease progression accord TIL availability . Patients follow every 6 month . PROJECTED ACCRUAL : A total 20-30 patient melanoma 20-30 patient renal cell carcinoma accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Cimetidine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologic evidence type cancer metastases Melanoma renal cell cancer prefer No active brain metastasis Tumor infiltrating lymphocyte must available Measurable evaluable disease prefer PATIENT CHARACTERISTICS : Age : 18 ( 75 prefer ) Performance status : ECOG 03 ( ECOG 0 1 prefer ) Hematopoietic : ( prefer ) WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hematocrit least 30 % ( transfusion allow ) Hepatic : ( prefer ) Bilirubin le 2.0 mg/dL PT/PTT normal Renal : ( prefer ) Creatinine le 2.0 mg/dL Cardiovascular : ( prefer ) At least 6 month since prior myocardial infarction No congestive heart failure , cardiac arrhythmia , hypertension require medication Pulmonary : ( prefer ) pO2 least 60 mm Hg Reasonable respiratory reserve No supplemental oxygen requirement Not dyspneic rest Other : No chronic autocoagulation ( prefer ) No active infection No chronic underlie immunodeficiency disease ( include HIV , hepatitis B ) No know autoimmune disease Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy ( 7 day since stereotactic radiosurgery ) Surgery : At least 4 week since prior surgery control brain metastases No prior organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>